Welcome to our dedicated page for Puma Biotechnology SEC filings (Ticker: PBYI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Puma Biotechnology SEC filings document an oncology biopharmaceutical business whose reported net product revenue comes from sales of NERLYNX®, its commercial oral neratinib product for HER2-positive breast cancer. Form 8-K reports furnish quarterly and annual operating results, financial-condition updates and exhibit press releases, including disclosures on revenue categories, cost of sales and guidance.
Proxy materials cover board matters, executive compensation and equity-award information, while material-event filings record governance actions such as amendments to the company’s bylaws. The filing record also provides formal context for common stock listed on the Nasdaq Global Select Market and development disclosures related to alisertib and Puma’s oncology programs.
Puma Biotechnology reported a small net loss for the first quarter of 2026 as higher research spending offset steady sales of its cancer drug NERLYNX. Total revenue was $44.8 million, slightly below $46.0 million a year earlier, as product and royalty revenue both declined modestly.
Operating costs rose to $48.6 million from $42.0 million, driven mainly by research and development expenses increasing to $19.8 million from $13.9 million. The company posted a net loss of $3.8 million, or $0.07 per share, compared with net income of $3.0 million, or $0.06 per share, in the prior-year quarter.
Despite the loss, Puma generated $15.4 million of cash from operating activities and ended the quarter with $101.5 million in cash, cash equivalents and marketable securities. Long-term debt under the Athyrium Notes was largely repaid, with $11.3 million classified as current, and stockholders’ equity stood at $128.4 million. Management believes existing cash and expected receipts from product sales and sub-license payments can fund operations for at least one year after this report.
Puma Biotechnology reported first quarter 2026 revenue of $44.8 million, slightly below $46.0 million a year earlier, as NERLYNX® net product revenue eased to $42.0 million from $43.1 million. The company posted a GAAP net loss of $3.8 million, versus net income of $3.0 million in 2025, while non-GAAP adjusted net loss was $1.9 million.
Research and development spending rose to $19.8 million, driven mainly by higher clinical trial costs for alisertib. Cash, cash equivalents and marketable securities were $101.5 million at March 31, 2026, and total debt fell to $11.3 million before being fully repaid on May 4, 2026.
Puma raised its 2026 outlook, guiding to total revenue of $222–$229 million and net income of $16–$19 million, up from prior ranges of $214–$221 million and $10–$13 million. Second quarter 2026 guidance calls for total revenue of $52–$55 million and net income of $2–$4 million, reflecting expectations for continued NERLYNX demand and ongoing alisertib development.
Puma Biotechnology, Inc. is asking stockholders to vote at its annual meeting on June 11, 2026 at its Los Angeles headquarters. Proposals include electing eight directors for one-year terms, ratifying KPMG LLP as independent auditor, and an advisory say-on-pay vote on executive compensation.
Stockholders are also asked to approve an Auerbach Warrant Amendment, extending the expiration of CEO Alan H. Auerbach’s warrant to purchase 2,116,250 common shares at $16.00 per share from October 4, 2026 to October 4, 2028. Holders of 50,891,675 outstanding common shares as of April 13, 2026 may vote in person or by proxy.
Puma Biotechnology, Inc. is asking shareholders to vote at its annual meeting on June 11, 2026 on four named proposals: election of eight directors, ratification of KPMG LLP as independent auditors, an advisory say-on-pay vote, and approval to extend the Auerbach Warrant expiration from October 4, 2026 to October 4, 2028. Shares entitled to vote were those of record on April 13, 2026; the filing states 50,891,675 shares outstanding as of that date. The Board recommends a vote FOR each proposal.
Puma Biotechnology Inc Schedule 13G/A shows The Vanguard Group reports 0 shares beneficially owned of Common Stock, representing 0% of the class.
The filing states Vanguard completed an internal realignment on January 12, 2026, after which certain subsidiaries report ownership separately in reliance on SEC Release No. 34-39538. The report is signed by Ashley Grim, Head of Global Fund Administration.
Puma Biotechnology, Inc. is a biopharmaceutical company focused on cancer treatments, led by its commercial drug NERLYNX for certain HER2-positive breast cancers and the investigational Aurora Kinase A inhibitor alisertib.
NERLYNX is approved in the United States for extended adjuvant early stage HER2-overexpressed/amplified breast cancer after trastuzumab-based therapy and, with capecitabine, for advanced or metastatic HER2-positive disease after at least two prior anti‑HER2 regimens. It is also approved for extended adjuvant and/or metastatic HER2-positive breast cancer in more than 40 countries through regional sub-license partners.
Alisertib has shown activity across multiple cancers and is now in Phase II trials for extensive-stage small cell lung cancer and HER2‑negative, hormone receptor‑positive metastatic breast cancer, with enrollment in the breast cancer trial completed in February 2026. Puma supports NERLYNX in the U.S. with a specialty oncology sales force of about 35 sales specialists and maintains a broad patent estate around neratinib and alisertib, with key U.S. neratinib protection currently extending to 2030. As of February 23, 2026, there were 50,876,487 shares of common stock outstanding, and the aggregate market value of voting stock held by non‑affiliates was approximately $145.2 million as of June 30, 2025.
Puma Biotechnology reported higher fourth quarter 2025 revenue but flat full-year sales, while remaining profitable for a third straight year. Q4 2025 total revenue was $75.5 million, up from $59.1 million, driven by NERLYNX product revenue of $59.9 million and royalty revenue of $15.6 million. GAAP net income for the quarter was $13.4 million, or $0.26 per diluted share, down from $19.3 million, largely reflecting valuation allowance effects.
For full year 2025, total revenue was $228.4 million versus $230.5 million in 2024, while GAAP net income inched up to $31.1 million, or $0.61 per diluted share. Non-GAAP adjusted net income was $38.1 million. Operating cash flow strengthened to $41.8 million, and total debt declined sharply to $22.5 million from $67.0 million, improving the balance sheet.
For 2026, Puma guides total revenue to $214–$221 million and GAAP net income of $10–$13 million, implying lower profit than 2025 as it invests in R&D. The company highlighted ongoing Phase II ALISCA™-Breast1 and ALISCA™-Lung1 trials, with multiple clinical data readouts expected in 2026 alongside continued commercialization of NERLYNX.
PUMA BIOTECHNOLOGY, INC. President and CEO Alan H. Auerbach reported equity awards that increase his direct holdings. On February 18, 2026, he received a grant of stock options for 227,474 shares at an exercise price of $0.00 per share.
On the same date, he was also granted 159,778 shares of common stock in the form of restricted stock units. Both the RSUs and the options vest in four equal installments on July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to continued employment and possible acceleration in certain events.
PUMA BIOTECHNOLOGY, INC. executive Douglas M. Hunt reported new equity awards consisting of stock options and restricted stock units. He was granted stock options for 70,321 shares at no exercise price shown here and 49,394 restricted stock units, both in direct ownership. These awards vest in four equal installments on July 1, 2026, January 1, 2027, July 1, 2027, and January 1, 2028, conditioned on his continued service with the company through each vesting date.